Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
clinical study
|
| gptkbp:ageRange |
18 years and older
|
| gptkbp:clinicalTrials.govIdentifier |
NCT03701022
|
| gptkbp:condition |
gptkb:acute_myeloid_leukemia
|
| gptkbp:enrollment |
approximately 180 participants
|
| gptkbp:focusesOn |
relapsed/refractory acute myeloid leukemia
|
| gptkbp:fullName |
FELIX: A Phase 2/3 Study of UCART123 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
| https://www.w3.org/2000/01/rdf-schema#label |
FELIX study
|
| gptkbp:intervention |
gptkb:UCART123
genetically modified T-cells |
| gptkbp:location |
gptkb:Europe
gptkb:United_States |
| gptkbp:period |
Phase 2/3
|
| gptkbp:principalInvestigator |
Julien Valton
|
| gptkbp:result |
overall response rate
|
| gptkbp:sponsor |
Cellectis S.A.
|
| gptkbp:startDate |
2018
|
| gptkbp:status |
recruiting
|
| gptkbp:studyType |
interventional
|
| gptkbp:bfsParent |
gptkb:Autolus_Therapeutics
|
| gptkbp:bfsLayer |
7
|